2021 Advanced Prostate Cancer Guideline Plenary

At the conclusion of the activity, participants will be able to:

• Discuss the 2020 AUA/ASTRO/SUO Guideline for the management of advanced prostate cancer.

Prostate Cancer Update 2021

At the conclusion of the activity, participants will be able to:

• Cite important new publications in this field during the past year.

• Identify the relative strengths and weaknesses of the reports.

• Appraise how new studies relate to the existing state-of-the-art in clinical practice.

• Analyze whether they and their colleagues should consider changing their practice based on the new

AUA Guideline Amendment: Muscle Invasive Bladder Cancer/Non-Muscle Invasive Bladder Cancer

At the conclusion of the activity, participants will be able to:

• Explain the 2020 amendments to the SUO/AUA Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer Guidelines, including what to do if bacillus Calmette-Guérin (BCG) is unavailable.

First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm

At the conclusion of the activity, participants will be able to:

• Analyze recent studies on first and second line therapies for treatment for advanced urothelial cancer.

Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems 

At the conclusion of the activity, participants will be able to:

• Implement current practice guidelines into the office setting.

• Identify the best intravesical agent and duration of therapy for low, intermediate, and high risk settings and what to do during a BCG shortage.

• Identify methods to treat significant toxicities from various intravesical therapies.

• Define high risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.

• Discuss the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and become familiar with current clinical trial designs

Advanced Renal Cell Carcinoma and Surgical Management of T1b and Hilar Renal Masses

At the conclusion of the activity, participants will be able to:

• Manage bleeding complications of robotic partial nephrectomy

• Describe the algorithm of immunotherapy treatment of advanced renal cell carcinoma

• Minimize positive margin rates of robotic partial nephrectomy

Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics

At the conclusion of the activity, participants will be able to:

• Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.

• Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients.

• Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.

• Demonstrate an understanding of advances in genomic testing and personalized medicine for urologic cancers.

• Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.

Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

At the conclusion of the activity, participants will be able to:

• Describe the standard of care chemotherapy regimens for genitourinary malignancies.

• Recall both historical and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates.

• Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies.

• Recognize and manage the adverse events related to these agents and the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies.

• List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.